VARIANTS OF ASSOCIATIONS KLINIKO-BIOCHEMICAL PARAMETERS AND CYTOKINES AT CIRRHOSIS OF LIVER OF VIRAL ETIOLOGY AT OF THE VARIOUS LEVELS OF PORTAL PRESSURE

Аim. For the early diagnosis of complications in liver cirrhosis, the degree of interrelation between clinical and biochemical blood indices and cytokines was studied.

Materials and methods. In 107 patients with cirrhosis of viral etiology of classes A, B, C on the Child–Pugh has been studied  indexes of clinical and laboratory syndromes were determined for  liver cirrhosis cases of Class A, B, C according to Chad–Pugh and the degree of their interrelation with IL-2, IL-6 and TNF-a was determined.

Results. Correlation is found between erythrocytes and IL-2, IL-6 in  liver cases of class A, erythrocytes and IL-2, IL-6 in liver cases of  class C. Correlation is found between leukocytes and IL-6 in liver  cases of class A, between leukocytes and IL-6 in liver cases of class  C, between leukocytes and TNF-a in liver cases of class C.  Correlation is found between thrombocytes and TNF-a in liver cases  of class A. Correlation is found between prothrombinand IL-2 in liver  cases of class A, between prothrombin and IL-2 in liver cases of class C, between prothrombin and IL-6, PTT, between IL-2 andfibrinase,  SMFC in liver cases of class A. Conclusion. The correlation of blood  indexes and the level of cytokines was found to be dependent on a  series of factors. 

1. Fuster D., Tsui J.I., Cheng D.M. Interleukin-6 is associated with noninvasive markers of liver fibrosis in HIV-infected patients with alcohol problems. AIDS Res. Hum. Retroviruses, 2013, Vol. 29 (8), pp. 1110–1116.

2. Мироджанов Г.К., Авезов С.А., Гиясов М.М., Абдуллаева З.М. Интерлейкин-6 и оксид азота в патогенезе портальной гипертензии и декомпенсации цирроза печени // Клиническая медицина. 2012. № 1. С. 47–53. [Mirodzhnov G.K., Avezov S.A., Giyazov M.M., Abdullayeva Z.M. Interleukin-6 and nitric oxide in pathogenesis of portal hypertension and decompensation of cirrhosis of the liver. Clinical Medicine, 2012, No. 1, pp. 47–53 (In Russ.)].

3. Назыров Ф.Г., Девятов А.В., Бабаджанов А.Х., Раимов С.А. Особенности развития и течения осложнений цирроза печени в зависимости от этиологического фактора // Новости хирургии. 2013. № 4. С. 45–50. URL: http://doi.org/10.18484/2305-047.2013.4.45. [Nazyrov F.G., Deviatov A.V., Babadjanov A.H., Raimov S.A. Peculiarities of development and course of complications of liver cirrhosis depending on the etiological factor. News Surgery, 2013, No. 4, pp. 45–50. URL: http://doi.org/10.18484/2305-0047.2013.4.45 (In Russ.)].

4. Giannitrapani L., Soresi М., Balasus D. Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma. World J. Gastroenterol., 2013, Vol. 19 (16), pp. 2449–2455.

5. Li S., Huang X., Zhong H. Tumour necrosis factor alpha (TNF-a) genetic polymorphisms and the risk of autoimmune liver disease: a meta-analysis. J. Genet., 2013, Vol. 92 (3), pp. 617–628.

6. Iwakir Y., Groszmann R.J. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology, 2010, Vol. 43, pp. 122–130.

7. Osawa Y., Hoshi M., Yasuda I. Tumor necrosis factor- promotes cholestasis-induced liver fibrosis in the mouse through tissue inhibitor of metalloproteinase- 1 production in hepatic stellate cells. PloS One, 2013, Vol. 8 (6), pp. 65251–65262.

8. Handa P., Kowdley K.V. Chemokines: potent mediators of hepatic inflammation and fibrosis in chronic liver diseases. Ann. Hepatol. 2014, Vol. 13 (1), pp. 152–154.

9. Nagano T. Cytokine profile in the liver of primary biliary cirrhosis. J. Clin. Immunol., 2010, No. 19, pp. 422–426.

10. Lisman T., Porte R.J. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood, 2010, Vol. 116, pp. 878–885. URL: http://doi.org/10.1182/blood-2010-02-261891.

11. Васюк Ю.А., Дударенко О.П., Ющук Е.Н., Школьник Е.Л., Серова М.К. «Цитокиновая» модель патогенеза хронической сердечной недостаточности и возможности нового терапевтического подхода в лечении декомпенсированных больных // Рациональная фармакотерапия в кардиологии. 2006. № 4. С. 63–70. [Vasyuk Yu.A., Dudarenko O.P., Yushchuk E.N., Shkolnik E.L., Serova M.K. «Cytokine» model of pathogenesis of chronic heart failure and the possibility of a new therapeutic approach in the treatment of decompensated patients. Rational Pharmacotherapy in Cardiology, 2006, No. 4, pp. 63–70 (In Russ.)].

12. Кетлинский С.А., Симбирцев А.С. Цитокины. СПб.: Фолиант, 2008. 552 с. [Ketlinskiy S.A., Simbirtsev A.S. Cytokines. Saint-Petersburg: Folio, 2008, 552 p. (In Russ.)].

13. Насонов Е.Л., Самсонов М.Ю., Беленков Ю.Н. Иммунопатология застойной сердечной недостаточности: роль цитокинов // Кардиология. 1999. No. 3. C. 66–73. [Nasonov E.L., Samsonov M.Yu., Belenkov Yu.N. Immunopathology of congestive heart failure: the role of cytokines. Cardiology, 1999, No. 3, pp. 66–73 (In Russ.)].

14. Balligandf J.-L., Ungureanu-Longrois D., Simmons W.W. et al. Cytokine-inducible nitric oxide cynthase (iNOS) expression in cardiac myocytes: char acteridation and regulation of iNOS expression and detection of iNOS activity in single cardiac myocytes in vitro. J. Biol. Chem., 1994, No. 269, pp. 27580–27588.

15. Bautista L.E., Vera L.M., Arenas I.A., Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J. Hum. Hypertens., 2005, Vol. 19 (2), pp. 149–154.

16. Bergman M.R., Holycross B.J. Pharmacological modulation of myocardial tumor necrosis factor a production phosphodiesterasa inhibitore. Pharmacol. Exp. Ther., 1996, No. 44, pp. 247–254.

17. Habib F.M., Springall D.R., Davies G.J. et al. Tumor necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet, 1996, No. 93, pp. 704–711